270 related articles for article (PubMed ID: 2310832)
1. Allogeneic bone marrow transplantation for leukemia with marrow grafts depleted of lymphocytes by counterflow centrifugation.
Schattenberg A; De Witte T; Preijers F; Raemaekers J; Muus P; Van der Lely N; Boezeman J; Wessels J; Van Dijk B; Hoogenhout J
Blood; 1990 Mar; 75(6):1356-63. PubMed ID: 2310832
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic bone marrow transplantation for leukemia with marrow grafts treated by counterflow centrifugation.
De Witte T; Schattenberg A; Preijers F; Raymakers R; Muus P; Wessels J
Bone Marrow Transplant; 1993; 12 Suppl 3():S2-6. PubMed ID: 8124252
[TBL] [Abstract][Full Text] [Related]
3. Survival in first or second remission after lymphocyte-depleted transplantation for Philadelphia chromosome-positive CML in first chronic phase.
Schattenberg A; Preijers F; Mensink E; Bär B; Schaap N; Geurts van Kessel A; van der Maazen R; de Witte T
Bone Marrow Transplant; 1997 Jun; 19(12):1205-12. PubMed ID: 9208114
[TBL] [Abstract][Full Text] [Related]
4. Prevention of graft-versus-host disease by lymphocyte depletion of the bone marrow graft with use of counterflow centrifugation.
Haanen C; De Witte T; Plas A; Schattemberg T
Haematologica; 1991 Mar; 76 Suppl 1():22-8. PubMed ID: 1864551
[TBL] [Abstract][Full Text] [Related]
5. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
[TBL] [Abstract][Full Text] [Related]
6. Influence of the conditioning regimen on erythrocyte chimerism, graft-versus-host disease and relapse after allogeneic transplantation with lymphocyte depleted marrow.
Bär BM; Schattenberg A; De Man AJ; Hoogenhout MJ; Boezeman J; de Witte T
Bone Marrow Transplant; 1992 Jul; 10(1):45-52. PubMed ID: 1515878
[TBL] [Abstract][Full Text] [Related]
7. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission.
Soiffer RJ; Fairclough D; Robertson M; Alyea E; Anderson K; Freedman A; Bartlett-Pandite L; Fisher D; Schlossman RL; Stone R; Murray C; Freeman A; Marcus K; Mauch P; Nadler L; Ritz J
Blood; 1997 Apr; 89(8):3039-47. PubMed ID: 9108425
[TBL] [Abstract][Full Text] [Related]
8. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
9. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia.
Drobyski WR; Ash RC; Casper JT; McAuliffe T; Horowitz MM; Lawton C; Keever C; Baxter-Lowe LA; Camitta B; Garbrecht F
Blood; 1994 Apr; 83(7):1980-7. PubMed ID: 8142664
[TBL] [Abstract][Full Text] [Related]
10. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia.
Hessner MJ; Endean DJ; Casper JT; Horowitz MM; Keever-Taylor CA; Roth M; Flomenberg N; Drobyski WR
Blood; 1995 Nov; 86(10):3987-96. PubMed ID: 7579370
[TBL] [Abstract][Full Text] [Related]
11. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone.
Nademanee A; Schmidt GM; Parker P; Dagis AC; Stein A; Snyder DS; O'Donnell M; Smith EP; Stepan DE; Molina A
Blood; 1995 Aug; 86(3):1228-34. PubMed ID: 7620176
[TBL] [Abstract][Full Text] [Related]
12. Outcome of transplantation for standard-risk leukaemia with grafts depleted of lymphocytes after conditioning with an intensified regimen.
Schaap N; Schattenberg A; Bär B; Preijers F; Geurts van Kessel A; van der Maazen R; de Boo T; de Witte T
Br J Haematol; 1997 Sep; 98(3):750-9. PubMed ID: 9332335
[TBL] [Abstract][Full Text] [Related]
13. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia.
Huss R; Deeg HJ; Gooley T; Bryant E; Leisenring W; Clift R; Buckner CD; Martin P; Storb R; Appelbaum FR
Bone Marrow Transplant; 1996 Oct; 18(4):767-76. PubMed ID: 8899193
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow transplantation for children less than 2 years of age with acute myelogenous leukemia or myelodysplastic syndrome.
Woolfrey AE; Gooley TA; Sievers EL; Milner LA; Andrews RG; Walters M; Hoffmeister P; Hansen JA; Anasetti C; Bryant E; Appelbaum FR; Sanders JE
Blood; 1998 Nov; 92(10):3546-56. PubMed ID: 9808546
[TBL] [Abstract][Full Text] [Related]
15. Graft-versus-leukemia in bone marrow transplantation. The Advisory Committee of the International Bone Marrow Transplant Registry.
Gale RP; Horowitz MM
Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():94-7. PubMed ID: 2390646
[TBL] [Abstract][Full Text] [Related]
16. Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: results in 102 cases.
McGlave PB; Beatty P; Ash R; Hows JM
Blood; 1990 Apr; 75(8):1728-32. PubMed ID: 2328322
[TBL] [Abstract][Full Text] [Related]
17. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin.
Finke J; Bertz H; Schmoor C; Veelken H; Behringer D; Wäsch R; Kunzmann R; Heidecker L; Lang H; Meyer-König U; Mertelsmann R
Br J Haematol; 2000 Oct; 111(1):303-13. PubMed ID: 11091217
[TBL] [Abstract][Full Text] [Related]
19. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease.
Papadopoulos EB; Carabasi MH; Castro-Malaspina H; Childs BH; Mackinnon S; Boulad F; Gillio AP; Kernan NA; Small TN; Szabolcs P; Taylor J; Yahalom J; Collins NH; Bleau SA; Black PM; Heller G; O'Reilly RJ; Young JW
Blood; 1998 Feb; 91(3):1083-90. PubMed ID: 9446672
[TBL] [Abstract][Full Text] [Related]
20. Outcome of T cell-depleted transplantation after conditioning with an intensified regimen in patients aged 50 years or more is comparable with that in younger patients.
Schattenberg A; Schaap N; Preijers F; van der Maazen R; de Witte T
Bone Marrow Transplant; 2000 Jul; 26(1):17-22. PubMed ID: 10918401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
